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ABSTRACT Alzheimer’s disease is a debilitating neurodegenerative disorder associated with the abnormal self-assembly of
amyloid-b (Ab) peptides into ﬁbrillar species. N-methylated peptides homologous to the central hydrophobic core of the Ab
peptide are potent inhibitors of this aggregation process. In this work, we use fully atomistic molecular dynamics simulations to
study the interactions of the N-methylated peptide inhibitor Ab16–20m (Ac-Lys16-(Me)Leu17-Val18-(Me)Phe19-Phe20-NH2) with a
model protoﬁlament consisting of Alzheimer Ab16–22 peptides. Our simulations indicate that the inhibitor peptide can bind to
the protoﬁlament at four different sites: 1), at the edge of the protoﬁlament; 2), on the exposed face of a protoﬁlament layer; 3),
between the protoﬁlament layers; and 4), between the protoﬁlament strands. The different binding scenarios suggest several
mechanisms of ﬁbrillogenesis inhibition: 1), ﬁbril inhibition of longitudinal growth (in the direction of monomer deposition); 2),
ﬁbril inhibition of lateral growth (in the direction of protoﬁlament assembly); and 3), ﬁbril disassembly by strand removal and
perturbation of the periodicity of the protoﬁlament (disruption of ﬁbril morphology). Our simulations suggest that the Ab16-20m
inhibitor can act on both preﬁbrillar species and mature ﬁbers and that the speciﬁc mechanism of inhibition may depend on
the structural nature of the Ab aggregate. Disassembly of the ﬁbril can be explained by a mechanism through which the inhibitor
peptides bind to disaggregated or otherwise free Ab16–22 peptides in solution, leading to a shift in the equilibrium from a ﬁbrillar
state to one dominated by inhibitor-bound Ab16–22 peptides.
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the presence of amyloid plaques in the brain.
These extracellular deposits are ﬁbrous masses, composed
primarily of aggregates of amyloid-b (Ab) peptides. Ab pep-
tides are proteolytic byproducts of the Ab protein precursor
and are most commonly composed of 40 (Ab40) or 42 (Ab42)
amino acids. These peptides appear to be mainly unstructured
in their monomeric state but aggregate to form ﬁbrils with an
ordered cross-b sheet pattern (1,2). Both small aggregates
(including soluble oligomers and protoﬁbrils) as well as ma-
ture ﬁbrils display toxicity, although recent studies suggest
that the former may be more cytotoxic (3–5).
Signiﬁcant effort has been invested in ﬁnding means to
combat this debilitating disease. In particular, a major re-
search thrust has involved the development of compounds
capable of inhibiting and reversing the aggregation process
(6–8). Based on the observation that the hydrophobic core of
the Ab peptide (residues 17–20: Leu17-Val18-Phe19-Phe20)
is critical for aggregation (9–12), Soto and co-workers de-
signed inhibitor peptides that bind speciﬁcally to this region
and prevent b-sheet formation (13). In the same spirit, a
number of research groups designed several other inhibitor
peptides adapted from this core sequence. These include
peptides containing the 17–20 segment without alterations
(12). Other strategies involved using peptides homologous
to the hydrophobic core of Ab in which elements disruptive
to aggregation were inserted (14–16). In this vein, peptide
N-methylation has emerged as a powerful strategy for inhibition
(17–21). Meredith and co-workers have recently demonstrated
that the membrane-permeable N-methylated pentapeptide
Ab16–20m (Ac-Lys16-(Me)Leu17-Val18-(Me)Phe19-Phe20-
NH2) (22) is an effective ﬁbrillogenesis inhibitor, capable
of both preventing ﬁbril growth and disassembling existing
ﬁbrils. The Ab16–20m peptide was designed such that the
N-methyl groups are placed at alternating positions along the
chain. As a result of this selective replacement of the amide
proton and the steric effects caused by the methyl group (21),
the peptide shows one face capable of hydrogen bonding
with the ﬁbril and one in which hydrogen bonding is pre-
vented. Because it has been shown that Ab ﬁbrils can grow
by monomer deposition (23), it has been proposed that the
N-methyl inhibitor peptide will cap the growing ﬁbril and pre-
vent further addition of monomer units. However, this theory
does not explain how and why the ﬁbril should disassemble.
In this article, we present a molecular dynamics (MD)
investigation of the interaction of the Ab16–20m peptide
with a model Ab16–22 protoﬁlament. The Ab16–22 peptide
(Ac-Lys16-Leu17-Val18-Phe19-Phe20-Ala21-Glu22-NH2) is one
of the shortest fragments of the Ab peptide capable of aggre-
gating into ﬁbrils (24). Furthermore, these ﬁbrils have been
extensively characterized by solid-state NMR (24). Our aim
is to elucidate the mechanism by which this peptide binds to
the ﬁbril, prevents its further growth, and triggers its dis-
assembly. Understanding this process will not only enable
the rational design of new N-methyl inhibitors but will also
lead to insights into the factors stabilizing ﬁbrils. A striking
result from our simulations is that the inhibitor peptide can
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bind in multiple ways to the ﬁbril, leading to several different
mechanisms of inhibition.
MATERIALS AND METHODS
In all our simulations the GROMOS96 force ﬁeld (25) was used to describe
the solute and the simple point charge (spc) water model to describe the
solvent (26). The temperature was maintained close to 300 K by weak cou-
pling to an external temperature bath (27) with a coupling constant of 0.1 ps.
The LINCS (28) algorithm was used to constrain bond lengths within the
solute. The SETTLE (29) algorithm was used to constrain the bond lengths
and the bond angle in water. The integration time step was 2 fs. A twin-range
cutoff of 0.9/1.4 nm was used to evaluate the nonbonded interactions. Inter-
actions within the short-range cutoff were evaluated every step, whereas in-
teractions within the long cutoff were updated every ﬁve steps, together with
the pair list. A reaction ﬁeld (RF) correction (30) with an eRF¼ 78 was used to
correct for the neglect of electrostatic interactions beyond the 1.4 nm cutoff.
Charge states were set in accordance with a pH of 7 and no counterions were
added (31). All simulations were performed using the GROMACS3.x software
package (32,33).
Monomer Ab16–20, Ab16–20m,
and Ab16–22 simulations
The structure of the N-methylated Ab16–20m was parameterized following
the Gromos 96 force ﬁeld manual (34) and then validated by comparing with
a density functional theory-optimized structure. To sample thermodynamic-
relevant states accessible to the peptide, fully atomistic MD simulations and
replica-exchange MD simulations (REMD) (35) in explicit solvent were
performed. Each structure was placed in a dodecahedral periodic box of
volume 45 nm3. The REMD simulations were carried out at 34 temperatures
ranging from 300 K to 550 K for a total of 50 ns per replica, giving a total
combined time of 1.7 ms for each peptide, with swap attempts every 10 ps.
Acceptance ratios for exchange moves ranged from 13% to 31%. The initial
structure for each replica was taken, after equilibration, at the closest desired
temperature from an inverse simulated annealing trajectory (slow heating) at
constant volume. The inverse simulated annealing scheme started at 300 K.
The temperature was linearly increased by 10 K during 40 ps, followed by
40 ps of simulation coupled to the new temperature and repeated until a ﬁnal
temperature of 550 K was reached.
Dimer and trimer simulations of Ab16–22
and Ab16–20m
Homodimers of Ab16–22 and Ab16–20m as well as mixed dimers of
Ab16–22 and Ab16–20m and heterotrimers of two Ab16–20m and one
Ab16–22 peptides were simulated using REMD. Each conﬁguration was
randomly generated and placed in a dodecahedral periodic box of volume
87 nm3. The REMD simulations were carried out at 34 temperatures ranging
from 300 K to 550 K for a total of 50 ns per replica, with swap attempts
every 100 ps. Acceptance ratios for exchange moves ranged from 6% to
33%. Two independent 50 ns REMD trajectories (each with different random
starting conﬁgurations) were run, giving a total combined time of 3.4 ms for
each system.
Protoﬁlament and protoﬁlament with
inhibitor simulations
The initial structure of the model protoﬁlament was generated by translations
and rotations of a single b-strand of Ab16–22 (Ac-Lys16-Leu17-Val18-
Phe19-Phe20-Ala21-Glu22-NH2) to form a bilayer, with each sheet consisting
of nine peptides. Adjacent strands in a layer were oriented antiparallel (24) to
each other with an initial Ca average separation distance of 0.45 nm. The
layers were oriented parallel to each other, with an initial separation distance
of 0.82 nm and such that the charged side chains were pointing to the solvent
(36). The volume of the dodecahedral box was 246 nm3. The density of
the system was adjusted by weak coupling to an external pressure bath (27)
(P0¼ 1 bar, coupling time tp¼ 1.0 ps). To initiate the MD simulations, each
system was ﬁrst energy minimized using a steepest descent algorithm. The
solvent was then relaxed by simulating the system with the solute position-
ally restrained (100 ps). Initial velocities were generated from a Maxwellian
distribution at the target temperature. For the protoﬁlament alone, two inde-
pendent 100 ns trajectories at room temperature were generated and a repre-
sentative structure taken as the structure with the lowest root mean-square
deviation (RMSD) of main chain atom distances with respect to the average
structure of the MD-generated ensemble. A protoﬁlament is a building block
of a ﬁbril and consists itself of one or more b-sheets.
The protoﬁlament used here has dimensions (diameter ,3.5 nm) corre-
sponding to the conventional deﬁnition of a ‘‘protoﬁlament’’. Four different
conﬁgurations of the Ab1622 protoﬁlament with Ab16–20m inhibitors,
named ConfA, ConfB, ConfC, and ConfD, were generated (see Fig. 5 b).
The initial conﬁguration of each conformation was built using the repre-
sentative structure of the protoﬁlament and a representative structure of the
Ab1620m inhibitor. In conformations ConfA, ConfB, and ConfD, two
inhibitors, one per protoﬁlament layer, were placed at different distances
from a single edge of the protoﬁlament until a critical distance was found
such that the inhibitor will approach the protoﬁlament. This critical distance
depends on the parameters of the force ﬁeld used, the treatment of electro-
statics, and the timescale of the simulations. Different orientations of the
inhibitor with respect to the chain at the edge of the protoﬁlament were tested
(parallel and antiparallel) as well as different faces (N-methyl groups toward
or away from the chain at the edge of the ﬁbril). In ConfC, two inhibitors per
protoﬁlament layer were placed at both edges of the protoﬁlament for a total
of four inhibitors. Each trajectory of the protoﬁlament with inhibitors was
monitored for 50 ns.
Cluster analysis
For each monomer simulation, a series of nonoverlapping clusters of struc-
tures were obtained as described in Daura et al. (37) by calculating the back-
bone RMSD between all pairs of structures (sampled every 0.04 ns) after a
best ﬁt rotation. Then, the structure with the largest number of neighbors that
satisfy the conditionRSMD, 0.08 nm (considered the central structure of the
cluster) was taken together with the neighbors to form the (ﬁrst) cluster and
eliminated from the pool of structures. This process was repeated until the
pool of structures was empty. For the dimer and trimer simulations, basins
representing the lowest energy structures were deﬁned based on the reaction
coordinates used to make the potential of mean force (PMF) plots in Figs. 3
and 4. Structures taken from replicas at all temperatures which fell into these
basinswere clustered based onCa positions of nonterminal residues (residues
17–19 for Ab16–20m and 17–21 for Ab16–22) using a cutoff of 0.25 nm.
Potential of mean force
One- and two-dimensional potentials of mean force along a number of re-
action coordinates at different temperatures were built using the weighted
histogram analysis method (38,39), which provides an optimal estimate of
the density of states. The reaction coordinates used include the number of Ca
contacts and the angle between the strands. A Ca contact is deﬁned if any two
Ca atoms have a separation less than 0.65 nm. For the angle between the
strands, a vector was formed for each strand by connecting the Ca atoms of
two residues (18 and 20 in Ab16–22 or 17 and 19 in Ab16–20m), and the
angle, u, between the vectors was calculated such that u ¼ 0 for parallel
strands and u ¼ 180 for antiparallel strands.
3J-coupling constants
3J-coupling constants were calculated from the trajectories using the Karplus
relation:
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JHNa ¼ a  cos2u1 b  cosu1 c;
where a, b, and c were chosen equal to 6.4 Hz,1.4 Hz, and 1.9 Hz, respec-
tively, and u ¼ f-60, with f the backbone dihedral angle (40).
RESULTS AND DISCUSSION
N-methylation rigidiﬁes the Ab16–20m peptide
Experimentally, the Ab1620m inhibitor peptide has been
characterized using circular dichroism (CD) spectroscopy
and two-dimensional NMR (22). These studies indicate that
the N-methylated peptide adopts an extended or b-strand
conformation, whereas its unmethylated counterpart adopts a
random coil structure. The Ab16–20m peptide does not form
ﬁbrils and its conformation is remarkably stable in different
solvent conditions and resists chemical and thermal dena-
turation.
We characterized the conformational space sampled by the
Ab16–20m inhibitor peptide using REMD simulations in ex-
plicit solvent, with a cumulative simulation time of 1.7 ms. To
further establish the effect ofN-methylation on the structure of
the peptide, a reference REMD simulation of the unmethy-
lated Ab16–20 was performed.
Conformations obtained from the REMD simulations
were clustered according to mutual RMSD. The end-to-end
distance distribution (a measure of the size of the peptide),
along with representative structures of the Ab16–20 and
Ab16–20m peptides obtained from the clustering analysis at
room temperature, are shown in Fig. 1. The conformational
space accessible to the Ab16–20m peptide is more restricted
than for the unmethylated peptide, with the Ab16–20m
peptide exhibiting a narrow peak at distances corresponding
to extended conformations (;1.24 nm). The unmethylated
peptide, on the other hand, shows a broader distribution of end-
to-end distances, corresponding to a greater variety of possible
conformations for the peptide. JNHa coupling constants
calculated from the REMD trajectory at room temperature
for Ab16–20m fall in the .7 Hz range characteristic of
b-strand conformation (22).
Two-dimensional potentials of mean force, plotted at room
temperature as a function of the backbone dihedral f and c
angles for Ab16–20 and Ab16–20m, illustrate the conforma-
tional restrictions arising from the N-methylation (Fig. 2). In
particular, the difference in dihedral space sampled by Lys16
and Val18 is striking. In the methylated peptide these two
residues are clearly conﬁned to the b-strand region, whereas
in the unmethylated peptide these two residues are free to
sample a broader region in dihedral space. The backbone di-
hedral angle f sampled by the methylated residues, mLeu17
and mPhe19, populates a signiﬁcant region in the range f. 0
(although no turn structure was observed), another mani-
festation of steric effects introduced by the methyl group.
The coexistence of the diverse ensemble of conformers for
Ab16–20 likely accounts for the random-coil CD seen ex-
perimentally, whereas the restricted conformations observed
here for Ab16–20m are consistent with the shifted b-strand
CD proﬁle (22).
Binding of the inhibitor peptide Ab16–20m
to free Ab16–22 peptides
The ability of the inhibitor peptide to bind to free Ab16–22
peptides in solution was investigated using replica exchange
MD simulations. An initial ‘‘benchmark’’ simulation was per-
formed to determine the preferred dimer conformations for
the Ab16–22 peptide. The ability of Ab16–22 to dimerize and
form larger aggregates has been previously investigated by
Gnanakaran et al. (41) and Nguyen et al. (42). The PMF for
the Ab16–22 dimer at 300 K is shown in Fig. 3 a. The PMF
as a function of the number of Ca contacts and the angle
between the two peptides shows two basins, a deeper one
corresponding to an antiparallel orientation (Fig. 3 c) and a
shallower one corresponding to a parallel orientation of the
two strands (Fig. 3 b). The antiparallel conﬁguration is the
lowest in energy. Ab16–22 homodimers display a range of
registries with a clear preference for the lysine residue to be
bound, whereas the glutamic acid residue favors a more sol-
vated conformation. Other higher energy dimer conﬁgurations
correspond to less-ordered, ‘‘bent’’ assemblies. Temperature-
dependent studies of the PMF projected onto the number of
FIGURE 1 Plot of the distribution of the end-to-end distance and of the central
structures of the most populated conformational clusters of the Ab16–20 and
Ab16–20m peptides. The N-methyl groups are highlighted in magenta. There
is a clear peak in the end-to-end distance distribution of the Ab16–20m
peptide indicating that this peptide resides preferentially in an extended
conformation. This dominant conformation exhibits a relative population of
;50% for the peptide ensemble sampled.
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interpeptide Ca contacts (see Supplementary Material) indi-
cate that the Ab16–22 dimer is the preferred conformation
over the entire range of temperatures studied (300–550), with
the Ab16–22 monomer basin residing much higher in energy.
A second benchmark simulation was performed to investi-
gate the inhibitor peptide’s ability to self-dimerize. Fig. 3 d
shows the PMF of the Ab16–20m dimer at 300 K as a
function of the number of Ca contacts and the angle between
the two peptides. Representative dimer conﬁgurations are
shown in Fig. 3, e and f. As in the case of Ab16–22, the
dimers can adopt a parallel or antiparallel orientation, with
the antiparallel conﬁguration lower in energy. Inhibitor
homodimers accommodate mainly in-registry with a lower
population of out-of-registry dimers. The less-ordered, bent
conﬁgurations seen for the Ab16–22 dimers are not ob-
served here. This is a direct result of the rigidiﬁcation im-
parted by the N-methylation. In all dimer conﬁgurations, the
N-methyl groups point to the solvent. Hence, these dimers
correspond to end-products, to which no further monomer can
add on. This is consistent with the experimental observation
that the N-methylated peptides cannot form ﬁbrils (22).
Unlike the Ab16–22 peptide that preferentially adopts a
dimer conformation, the Ab16–20m peptide coexists be-
tween monomeric and dimeric forms. In fact, the dimeric
states of Ab16–20m are stable only at temperatures below
310 K. At higher temperatures, diverse dimer conformations
which are neither parallel nor antiparallel are short lived, and
the monomer state becomes dominant (see Supplementary
Material). This ﬁnding is consistent with the inability of
the Ab16–20m inhibitor to form ﬁbrils. The Ab16–22 dimers,
on the other hand, display two well-deﬁned temperature-
dependent basins, with a basin representing monomeric states
that develops at slightly higher temperature than 300 K and
remaining at high temperatures but always higher in free
energy than the dimeric basin.
After the benchmark homodimer simulations, we performed
a series of simulations to probe how the inhibitor peptide binds
free Ab16–22 peptides in solution. We consider ﬁrst the inter-
action of one inhibitor Ab16–20m peptide with one Ab16–22
peptide, followed by the interaction of two inhibitor Ab16–
20m peptideswith oneAb16–22 peptide. The latter simulation
mimics experimental conditions in which the inhibitor/peptide
ratio is at least 2:1 (typical ratios used in the experiment ranged
between 2:1 and 10:1) (22).
For the system of one Ab16–20m peptide with one Ab16–
22 peptide, we ﬁnd that at room temperature, the preferred
state is one in which the inhibitor peptide is bound to Ab16–
22. Parallel and antiparallel relative orientations with dif-
ferent backbone registries generate a rich pool of mixed dimer
conformations. Fig. 4 a shows a two-dimensional PMF as a
function of the number of peptide-inhibitor Ca contacts and
the angle between the two peptides, as well as representative
dimer conformations in Fig. 4, b and c. Interestingly, the de-
gree of conformational restriction of the mixed dimers, as
measured by the chosen reaction coordinates, lies in between
that of the inhibitor homodimer and the Ab16–22 homo-
dimer, which is consistent with the relative degree of ﬂex-
ibility of the two peptides.
Finally, we studied the interaction of two Ab16–20m
peptides with one Ab16–22 peptide. At room temperature, a
dominant free energy basin is present in the PMF plotted as a
function of the number of peptide-inhibitor Ca contacts and
the number of Ca contacts between the inhibitors (Fig. 4 d).
A projection of the free energy in Fig. 4 d onto the number of
FIGURE 2 Ramachandran plots for the (top row: a, c, e, and g) Ab16–20 peptides and (bottom row: b, d, f, and h) Ab16–20m peptides. a and b correspond
to Lys16, c and d to Leu17, e and f to Val18, and g and h to Phe19. The conformational effect induced by the N-methylation results in the restriction of the dihedral
space of residues (b) Lys16 and (f) Val18.
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Ca inhibitor-peptide contacts when the number of inhibitor-
inhibitor contacts is zero is shown in Fig. 2 of the Supple-
mentary Material. This ﬁgure shows that the minimum free
energy occurs at a number of Ca inhibitor-peptide contacts
of 30. The lowest energy basin corresponds to a structure in
which the Ab16–22 peptide is sandwiched between two inhi-
bitor peptides (snapshots of the centroids of the three most
populated clusters, C1, C2, and C3 are shown in Fig. 4, e–g).
In all three representative structures, one inhibitor mole-
cule is bound to the Ab16–22 peptide via ﬁve (C1 and C2) or
six (C3) hydrogen bonds in an antiparallel alignment with
both N-methyl groups pointed toward the solvent. Likewise,
in all three structures, the second inhibitor molecule is bound
to the Ab16–22 peptide on the side opposite the ﬁrst. In the
two most populated clusters (C1 and C2, Fig. 4, e and f ) the
second inhibitor is bound across to the peptide with its
methyl groups either solvent exposed (C1) or pointing to-
ward the peptide (C2) and held in place by side-chain inter-
actions, in particular Phe-Phe interactions (C1) and Lys-Phe,
Val-Phe, and Leu-Leu interactions (C2). In the third most
populated cluster (Fig. 4 g), the second inhibitor is bound to
the Ab16–22 peptide via ﬁve hydrogen bonds in a parallel
orientation with its methyl groups solvent exposed. C4 (not
shown) is the all-antiparallel counterpart of C3 and com-
prises 6% of the structures in this basin. The higher-energy
basins present in Fig. 4 d correspond to structures present
mainly in the higher-temperature replicas in which the pep-
tide binds to one inhibitor or to neither inhibitor.
FIGURE 3 Two-dimensional PMF plots at T¼ 300K for the two homodimers
studied: (a) the Ab16–22 peptide and (d) the Ab16–20m inhibitor. In each
plot, the free energy is plotted in units of kJ/mol versus number of interpeptide
Ca contacts (x axis) and the cosine of u, the angle between the two peptides,
deﬁned as the angle between the vectors connecting Ca atoms of residues
17 and 19 in the Ab16–20m inhibitor and residues 18–20 in the Ab16–22
peptide. The boxes denote the region of phase space representing the lowest
energy basins in which conformational clustering was performed. (b–c, e–f)
The resulting representative structures from the most populated clusters within
these basins are shown on the right. Methyl groups are shown as gray spheres,
backbone interpeptide hydrogen bonds are shown as dotted lines, and the
N-terminus of each strand is highlighted in orange for the Ab16–20m inhib-
itor and in violet for the Ab16–22 peptide.
FIGURE 4 (a) Two-dimensional PMF plot at T ¼ 300 K for the Ab16–
20m inhibitor-Ab16–22 peptide dimer. The free energy is plotted in units of
kJ/mol versus number of interpeptide Ca contacts (x axis) and the cosine of
u, the angle between the two peptides, deﬁned as the angle between the
vectors connecting Ca atoms of residues 17 and 19 in the Ab16–20m
inhibitor and residues 18–20 in the Ab16–22 peptide. The boxes denote
the region of phase space representing the lowest energy basins in which
conformational clustering was performed. (b and c) The resulting represen-
tative structures from the most populated clusters within these basins are
shown on the right. Methyl groups are shown as gray spheres, backbone
interpeptide hydrogen bonds are shown as dotted lines, and the N-terminus
of each strand is highlighted in orange for the Ab16–20m inhibitor and in
violet for the Ab16–22 peptide. (d) Two-dimensional PMF plot for the
trimer consisting of two Ab16–20m inhibitors and one Ab16–22 peptide.
The free energy is plotted in units of kJ/mol versus number of Ab16–20m
inhibitor-Ab16–20m inhibitor Ca contacts (x axis) and the total number of
Ab16–22 peptide-Ab16–20m inhibitor contacts. The box denotes the region
of phase space representing the lowest energy basin in which conformational
clustering was performed. (e–g) The resulting representative structures from
the three most populated clusters within this basin are shown on the right.
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A plausible mechanism of action of the N-methylated pep-
tides would be to bind to the free Ab16–22 monomers in
solution, thus effectively sequestering these peptides from
the pool of available monomers for ﬁbril growth. Although a
direct competitive experiment involving a pool of free mono-
mers and a protoﬁlament is not computationally tractable
using fully atomistic, solvated simulations, this mechanism
is supported by the nature of the structures belonging to the
lowest free-energy basin. Not only would this process pre-
vent ﬁbril growth, it could also lead to ﬁbril disassembly.
Fibrils are dynamic entities, with monomers at the edges at-
taching and detaching. The inhibitor peptides could bind to
the departing monomers and remove them from active cir-
culation, shifting the equilibrium from aggregate to inhibitor-
bound monomer.
Binding of the inhibitor Ab16–20m to ordered
Ab16–22 aggregates
Structure of the Ab16–22 protoﬁlament
The nature of the arrangements of b-strands in ﬁbrils of
Ab16–22 has been investigated by solid-state NMRbyTycko
and co-workers (24). Their results reveal that the peptides
adopt anantiparallel arrangement, consistentwithother exper-
imental (43) and theoretical investigations (41,44–46). Based
on the available NMR data, we constructed a model proto-
ﬁlament consisting of two parallel sheets, each composed of
nine antiparallel Ab16–22 b-strands. Charged side chains
(Lys16 and Glu22) point toward the solvent, whereas the
Leu17, Phe19, and Ala21 residues form the hydrophobic in-
terior of the protoﬁlament. A snapshot of an equilibrated
protoﬁlament structure is shown in Fig. 5 a. We did not ob-
serve a signiﬁcant number of water molecules at the interior of
the protoﬁlament. The equilibrated protoﬁlament displays a
twist of average angle ;16 between adjacent strands and a
helical pitch of ;16 nm. The separation between the two
layers of the protoﬁlament ranged from 0.89 nm to 0.95 nm
during the course of two different 100-ns-long simulations.
The separation between each individual peptide chain in a
layer ranged from 0.43 nm to 0.53 nm, with an average value
of 0.47 nm. Both layer and strand separation distances are
consistent with the solid-state NMR values (0.99 nm and
0.47 nm, respectively (24)). The distribution off and c back-
bone dihedral angles of Leu17, Val18, Phe19, Phe20, and Ala21
(data not shown) remains in the characteristic range for anti-
parallel b-sheet structure during the course of the simulations
(47).
The overall in-register network of hydrogen bonds is stable
throughout both trajectories. There are about four backbone
hydrogen bonds between adjacent strandswithin each layer in
locations that repeat every two strands. The distance between
the Ca atoms of the ﬁrst and last residue of a given strand is on
average ;1.91 nm, slightly more extended than monomer
Ab16–22 in solution (basin of the extended conformation
centered at ;1.54 nm, see Supplementary Material). Root
mean-squared ﬂuctuations of the atomic positions indicate
that the ﬂexibility of the protoﬁlament is most pronounced for
the strands located at the extremities where the packing of the
side chains is less dense than in the center of the protoﬁlament
(data not shown). The twisting and bending seen in our
simulations contribute to the overall stability of the structure,
FIGURE 5 (a) Initial structure of the model protoﬁlament
generated by translations and rotations of a single b-strand
of Ab16–22 (Ace-Lys16 Leu17 Val18 Phe19 Phe20 Ala21
Glu22 -NH2). (b) Snapshots at 50 ns indicate four possible
scenarios for Ab1620m peptide binding to the Ab1622
protoﬁlament. In ConfA and ConfB the inhibitor binds at the
edge of the protoﬁlament via hydrogen-bond formation in
either parallel or antiparallel relative orientation to the edge
strand; the other inhibitor molecule shown in ConfB drifts
from the edge to the lateral side of the protoﬁlament and
intercalates in between the layers; in ConfC one inhibitor
binds to one of the solvent-exposed protoﬁlament faces and
across several strands of the protoﬁlament, with N-methyl
groups facing the protoﬁlament; in ConfD, two inhibitors
interact with an edge strand breaking the symmetry between
protoﬁlament layers. Animations illustrating the different
binding sites are shown in the Supplementary Material.
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as has been observed for other model protoﬁlaments (48).
Finally,wenote that a numberofother strandand sheet arrange-
ments have been proposed for ﬁbrils of Ab16–22 (such as, for
instance, an antiparallel strand arrangement in which the side
chains of Lys16, Val18, Phe20, and Glu22 point to the interior of
the ﬁbril) (49,50). However, the model used here has proved
to be the lowest energy and the most stable one within our
simulation protocol.
Binding of the inhibitor to the protoﬁlament
The interaction of the inhibitor peptide with the protoﬁlament
was monitored through 13 50-ns simulations (10 trajectories
for the system protoﬁlament—2 inhibitors and 3 trajectories
for the system protoﬁlament—4 inhibitors) and 4 20-ns
simulations (for the system protoﬁlament—2 inhibitors). The
different simulations were initiated with either two or four in-
hibitor peptides placed at different distances and orientations
from one edge of the protoﬁlament. These stoichiometric ra-
tios were chosen for their computational tractability and are
much lower (by ninefold in the case of two inhibitor mole-
cules and by 4.5-fold in the case of four inhibitor molecules)
than even the lowest inhibitor/Ab16–22 peptide ratios tested
experimentally (22).
Binding of the inhibitor to the protoﬁlament was seen in
all but one simulation. Competition simulations in which
both inhibitor peptide and free Ab16–22 peptide were placed
in solution with the ﬁbril only showed binding of the inhi-
bitor to the ﬁbril during the duration of the simulations (see
Fig. 4 of the Supplementary Material). Three distinct binding
scenarios emerge.
Fibril termination in the direction of monomer deposi-
tion. The most common scenario seen in our simulations
involves the binding of the inhibitor peptide to the edge of
the protoﬁlament via hydrogen bonding, with the N-methyl
groups exposed to the solvent (Fig. 5 b, Conf A). This bind-
ing event constitutes a means of terminating ﬁbril growth
in the longitudinal direction: additional Ab16–22 monomers
cannot form hydrogen bonds with the exposed N-methylated
side of the bound Ab16–20m peptide, and hence no further
deposition of Ab16–22 will take place.
Interestingly, the bound inhibitor shows backbone dihedral
angles consistent with b-strand secondary structure, with all
three nonmethylated residues involved in hydrogen bonds
with the protoﬁlament. The registry of backbone hydrogen
bonds, however, slightly differs in each binding event observed,
which is consistent with the varied pool of conformations ob-
served in our mixed di- and trimerization simulations. The
mLeu17, Val18, mPhe19, and Phe20 side chains of the inhibitor
form a stable hydrophobic cluster with either the Leu17, Val18,
Phe19, Phe20, or to a lesser extent with the Lys16 and Ala21
residues of the Ab16–22 b-strand of the protoﬁlament. The
side chain of residue Glu22 does not form a signiﬁcant number
of side-chain contacts with the inhibitor. In the process of
binding, there is no clear distinction in terms of inhibitor-
protoﬁlament interaction energy for parallel or antiparallel ori-
entation. The antiparallel arrangement has been proposed
as the most probable orientation in ﬁbrils formed of small
peptides with low amphiphilicity (51), but, interestingly, our
REMD simulations discussed here as well as recent REMD
simulations by Garcia show that the Ab16–22 peptide can
form both parallel and antiparallel dimers (41). Our simula-
tions suggest that the binding of the Ab1620m inhibitor
to the ﬁbril can be accommodated in both orientations, i.e.,
parallel and antiparallel, thus maximizing the possibilities of
interaction of the peptide with the ﬁbril (Fig. 5 b, ConfA and
ConfB). Such degeneracy in our model may arise from the
high afﬁnity of the short hydrophobic sequence, whose side
chains easily pack to each other without favoring any parti-
cular chainorientation. It is alsopossible that theparallel orien-
tation of the inhibitor with respect to the protoﬁlament peptide
chain is metastable and en route in the path toward antiparallel
binding, as supported by our dimer REMD simulations in
which the parallel basin is shallow whereas the antiparallel
is deep.
We postulate that the rigidity of Ab16–20m favors bind-
ing since the peptide end-to-end distance is already adjusted
to ﬁt the homologous sequence in the protoﬁlament. Indeed,
the end-to-end distance of the Ab16–20m in free monomeric
form is ;1.24 nm, comparable to its end-to-end distance
in dimers and trimers (;1.3 nm) and when bound to the
protoﬁlament (;1.24–1.28 nm). Furthermore, this distance
is consistent with the average distance of;1.27 nm between
the Ca atom of residues Lys16 and Phe20 for each strand of
the protoﬁlament. The Ab16–20m peptide hence appears to
be prestructured in its monomeric form in a state commen-
surate for binding to the protoﬁlament. This property could
enable the Ab16–20m to compete effectively for binding with
free Ab16–22 peptides in solution. The rigid N-methylated
peptide would display a smaller loss of conformational en-
tropy and hence more favorable free energy upon binding to
the ﬁbril than a ﬂexible Ab16–22 peptide. The Ab16–22
peptide would presumably have to either ﬁrst extend before
binding to the strand at the edge of the protoﬁlament or bind
and subsequently rearrange its structure.
Fibril inhibition in the direction of lateral growth. Binding
at the edge of the protoﬁlament is not the only way in which
the inhibitor peptide can interact with the protoﬁlament. Our
simulations reveal two other binding modes that can lead to
inhibition in the direction of lateral, rather than longitudinal,
growth.
The ﬁrst scenario involves the drifting of the inhibitor
peptide from the edge of the protoﬁlament to the side until it
is positioned between the layers (Fig. 5 b, ConfB), with the
Lys16 residue pointing to the solvent or, in other words, with
the hydrophobic residues inserted in between the protoﬁla-
ment layers. The interstrand distance for the two chains
closer to the site where the inhibitor has intercalated (in the
case of Fig. 5 b, ConfB strands number 6 and 7) considerably
increases from ;0.50 nm to ;0.61 nm in one layer but
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decreases in the other from ;0.45 nm to ;0.43 nm (Fig. 6,
ConfB), altering the geometry of the protoﬁlament. These
observations indicate that the inhibitor has the ability to
interact via its side chains in the dimension of lateral ﬁbril
growth, perpendicular to the elongation dimension. This is
an interesting possibility for inhibition because this binding
site could potentially stop further addition of layers, thus
preventing the formation and stabilization of mature ﬁbrils.
Two new simulations were started from the same initial
conﬁguration that Fig. 5 b ConfB was started from, but with
different initial velocities. In both new trajectories we ob-
served that, after 20ns, one of the inhibitors had hydrogen
bonded at the edge strand of the protoﬁlament and that the
other inhibitor had positioned itself between the layers. This
further conﬁrms the plausibility of this binding scenario.
A second scenario of lateral growth inhibition involves the
binding of the Ab16–20m peptide on a solvent-exposed face
of the protoﬁlament, rather than between the layers of the
protoﬁlament (Fig. 5 b, ConfC). This conﬁguration differs
from ConfA, ConfB, and ConfD in that there are four inhi-
bitors. Initially, each inhibitor is positioned at the bottom edge
of each protoﬁlament layer with the N-methyl side pointing
toward the solvent. During the simulation, one of the Ab16–
20m peptides drifts toward the center of the protoﬁlament
solvent-exposed face and rotates such that it binds across
several (three to four) protoﬁlament strands with the
N-methylated side of the inhibitor facing the protoﬁlament.
Due to ﬂuctuations in the position of the inhibitor throughout
the simulation, some hydrogen bonds are made between the
inhibitor and the ﬁbril; however, the binding of this inhibitor
is mainly stabilized by contacts between the Ab16–20m side
chains and the protoﬁlament. Although all inhibitor residues
form a relatively high number of contacts with the side chain of
residue Phe20 of the protoﬁlament strands, the highest number
of side-chain contacts is between mPhe19 of the inhibitor and
Phe20 of the protoﬁlament. These simulations suggest that the
binding of the inhibitor via side-chain interactions on the
face of the protoﬁlament can block ﬁbril growth in the lateral
direction. Two additional 20 ns simulations started from the
same initial coordinates and different initial velocities con-
ﬁrmed this binding event. The experiments of Meredith and
co-workers (22) were performed with a higher ratio of
inhibitor/Ab16–22 peptide than used in our simulations, and
it is likely that under such conditions more than one inhibitor
could bind to the face of the aggregate. This mechanism
could be highly effective at inhibiting the growth of not only
preﬁbrillar species but of much larger ﬁbrils as well.
Protoﬁlament strand removal by the inhibitor. The
third scenario observed in our simulations involves two in-
hibitors simultaneously attacking the terminal strand residing
at the edge of the protoﬁlament (Fig. 5 b, ConfD). The ﬁrst
inhibitor binds to the edge strand of the ﬁbril, whereas the
second inhibitor intercalates between the edge strand and the
previous one. This conﬁguration would lead to a scenario
strikingly similar to the stable trimer shown in Fig. 4 g in
which an Ab16–22 peptide is isolated by two Ab16–20m
inhibitor molecules. This process could potentially lead to
disassembly of the ﬁbril by strand removal, one by one. This
is a particularly interesting scenario, as the protoﬁlament is
believed to grow in the longitudinal direction by monomer
deposition, and our inhibitor would be effectively reversing
this process. This mechanism of targeted strand removal is
quite plausible, given the high ratios of inhibitor required in
the experiments of Meredith and co-workers (22).
FIGURE 6 Interstrand distance for the model Ab1622
protoﬁlament in the absence and presence of the inhibitor
for each of the conﬁgurations (ConfA, B, C, and D) shown
in Fig. 5 b. For the protoﬁlament alone, the average value
of the interstrand distance in our trajectories converges to
the value reported by Tycko and co-workers (24). In the
cases where the inhibitor simply binds to the edge of
the protoﬁlament (Conf A) or binds on the exposed face of
the protoﬁlament (Conf C), the interstrand distances remain
mostly unaffected. In binding scenarios B and D, where the
inhibitor intercalates between the layers and strands, respec-
tively, the distance between protoﬁlament strands is
perturbed.
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Although a complete unbinding event was not observed on
the timescale of our simulation, we could nonetheless see
evidence of destabilization of the terminal strand. For the case
of the binding event shown in Fig. 5 b, ConfD, the interstrand
distance between the terminal strand (number 9) and the pre-
ceding strand (number 8), considerably increases from;0.47
nm to ;0.68 nm. Interestingly, this disruption also affected
the interstrand distance between strands 6 and 7 (Fig. 6,
ConfD). The charged group Lys16 of the inhibitor inserts
deeply between the strands (Fig. 5 b, ConfD). Insertion is
driven both by side-chain interaction with neighboring strands
and by the rigid nature of the inhibitor that eases intercalation
between the protoﬁlament strands. It is possible that this mode
of binding is more likely to occur in preﬁbrillar species than in
mature ﬁbrils. Indeed the loose-packing present in early oligo-
meric forms would lend itself more easily to insertion of inhi-
bitor molecules between strands.
The breaking of symmetry between the layers resulting
from strand removal in one layer may induce a destabiliza-
tion of the entire suprastructure of the ﬁbril. Simulations
were performed in which one or more strands were manually
removed from one layer of the protoﬁlament. During the
time course of our simulations (20 ns) the morphology of the
protoﬁlament became highly distorted, suggesting its even-
tual disruption (see Fig. 3 in Supplementary Material).
CONCLUSIONS
Our simulations reveal a much more complex mechanism of
inhibition for N-methylated peptides than was previously
thought. Our simulations suggest that the inhibitor can act in
two manners: 1), by binding to free Ab16–22 monomers in
solution, depleting the pool of available ﬁbril ‘‘building
blocks’’, and shifting the equilibrium from ﬁbrillar to mono-
mer; and 2), by binding to the protoﬁlament. We see different
binding sites along the protoﬁlament structure, consistent with
the presence of multiple binding sites identiﬁed in spectro-
scopic studies of ligands binding to Ab1–40 ﬁbrils (52,53).
Binding at different sites can lead to different mechanisms
by which ﬁbril growth is stopped, its structure destabilized,
and disassembly induced.
The dominant binding site of the N-methyl inhibitor
Ab1620m with the Ab16–22 protoﬁlament is at the edge
of the protoﬁlament via hydrogen bonds to prevent further
elongation. The binding sites which occurred less frequently
in our simulations correspond to insertion of the inhibitor in
between protoﬁlament layers and on the exposed face of a
protoﬁlament, both of which can stop lateral growth of the
ﬁbril. Finally, two inhibitors can act in concert to remove
peptide strands one by one from the edge of the protoﬁla-
ment. In all instances, binding of the inhibitor perturbed the
symmetry between layers and had an overall destabilizing
effect on the morphology of the ﬁbril. We believe that the
prestructuring of the N-methyl inhibitor favors binding since
the peptide is already accommodated to ﬁt the homologous
sequence in the Ab16–22 protoﬁlament. Our trimer simu-
lations of two inhibitors with one Ab16–22 peptide show
that the inhibitor would rather bind to Ab16–22 than to itself,
or remain in monomeric form. Furthermore, the dimer and
trimer structures which are formed (Fig. 4, e–g) in the REMD
simulations mimic the binding modes observed in the MD
simulation of the ﬁbril and inhibitors. Speciﬁcally, parallel
and antiparallel backbone hydrogen bonding of the inhibitor
molecules to the Ab16–22 peptide as well as binding via inter-
action of hydrophobic side chains were observed in both the
REMD and MD simulations. In addition, competition simu-
lations in which we placed both inhibitor and Ab16–22 pep-
tides in solution with the ﬁbril only showed binding of the
inhibitor to the ﬁbril in the timeframe of our simulation (50 ns
or less) (see Fig. 4 of the Supplementary Material).
Disassembly of the ﬁbril can be triggered by a destabili-
zation of the ﬁbril upon binding of the inhibitor or by the
sequential removal of the end strands (Fig. 5 b, Conf D).
Complete disassembly of the ﬁbril cannot be seen in our sim-
ulations, as this process occurs on timescales that are not com-
putationally accessible. The inhibitors can prevent reassembly
of the ﬁbril by binding to the disaggregated (or otherwise free)
Ab1622 peptides in solution (Fig. 4). Fibril disassembly
can hence be rationalized in terms of a population shift from
aggregate species to monomeric species. The high concen-
tration of inhibitors required in the experiment is consistent
with this idea, with the inhibitors binding to Ab1622
monomers or even Ab1622 preﬁbrillar species in solution.
The end result is a shift from a ﬁbril-dominated ensemble to
one populated by Ab16–22 monomers bound to inhibitor
peptides.
The ﬁbrillogenesis mechanisms we observed suggest that
theN-methylated inhibitor peptide can act on both preﬁbrillar
forms and on mature ﬁbrils of Ab16–22. These oligomeric
species coexist in solution, and the precise mode of action of
the inhibitor may depend on the nature of the aggregate
morphology. The structures in which binding of the inhibitor
at the edge of the protoﬁlament takes place could be the domi-
nant aggregate population. Less populated protoﬁlament
morphologies may facilitate lateral or interstrand inhibitor
binding. That N-methyl inhibitors act via different mecha-
nisms, not only by stopping strand deposition, has also been
suggested by Doig and co-workers to explain the effect of
N-methyl inhibitors on Ab25–35 ﬁbrillization (17). Ongoing
research in our group involves the investigation of the binding
of Ab16–20m to model protoﬁlaments of the longer Ab9–40
peptide (54).
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